

Patologia: Doenças Bacterianas e Fúngicas

Yvanna Carla de Souza Salgado
(Organizadora)



 **Atena**
Editora

Ano 2019

Yvanna Carla de Souza Salgado
(Organizadora)

**Patologia:
Doenças Bacterianas e Fúngicas**

Atena Editora
2019

2019 by Atena Editora

Copyright © da Atena Editora

Editora Chefe: Profª Drª Antonella Carvalho de Oliveira

Diagramação e Edição de Arte: Lorena Prestes e Geraldo Alves

Revisão: Os autores

Conselho Editorial

Prof. Dr. Alan Mario Zuffo – Universidade Federal de Mato Grosso do Sul
Prof. Dr. Álvaro Augusto de Borba Barreto – Universidade Federal de Pelotas
Prof. Dr. Antonio Carlos Frasson – Universidade Tecnológica Federal do Paraná
Prof. Dr. Antonio Isidro-Filho – Universidade de Brasília
Profª Drª Cristina Gaio – Universidade de Lisboa
Prof. Dr. Constantino Ribeiro de Oliveira Junior – Universidade Estadual de Ponta Grossa
Profª Drª Daiane Garabeli Trojan – Universidade Norte do Paraná
Prof. Dr. Darllan Collins da Cunha e Silva – Universidade Estadual Paulista
Profª Drª Deusilene Souza Vieira Dall’Acqua – Universidade Federal de Rondônia
Prof. Dr. Eloi Rufato Junior – Universidade Tecnológica Federal do Paraná
Prof. Dr. Fábio Steiner – Universidade Estadual de Mato Grosso do Sul
Prof. Dr. Gianfábio Pimentel Franco – Universidade Federal de Santa Maria
Prof. Dr. Gilmei Fleck – Universidade Estadual do Oeste do Paraná
Profª Drª Girlene Santos de Souza – Universidade Federal do Recôncavo da Bahia
Profª Drª Ivone Goulart Lopes – Istituto Internazionele delle Figlie de Maria Ausiliatrice
Profª Drª Juliane Sant’Ana Bento – Universidade Federal do Rio Grande do Sul
Prof. Dr. Julio Candido de Meirelles Junior – Universidade Federal Fluminense
Prof. Dr. Jorge González Aguilera – Universidade Federal de Mato Grosso do Sul
Profª Drª Lina Maria Gonçalves – Universidade Federal do Tocantins
Profª Drª Natiéli Piovesan – Instituto Federal do Rio Grande do Norte
Profª Drª Paola Andressa Scortegagna – Universidade Estadual de Ponta Grossa
Profª Drª Raissa Rachel Salustriano da Silva Matos – Universidade Federal do Maranhão
Prof. Dr. Ronilson Freitas de Souza – Universidade do Estado do Pará
Prof. Dr. Takeshy Tachizawa – Faculdade de Campo Limpo Paulista
Prof. Dr. Urandi João Rodrigues Junior – Universidade Federal do Oeste do Pará
Prof. Dr. Valdemar Antonio Paffaro Junior – Universidade Federal de Alfenas
Profª Drª Vanessa Bordin Viera – Universidade Federal de Campina Grande
Profª Drª Vanessa Lima Gonçalves – Universidade Estadual de Ponta Grossa
Prof. Dr. Willian Douglas Guilherme – Universidade Federal do Tocantins

Dados Internacionais de Catalogação na Publicação (CIP) (eDOC BRASIL, Belo Horizonte/MG)

P312 Patologia [recurso eletrônico]: doenças bacterianas e fúngicas /
Organizadora Yvanna Carla de Souza Salgado. – Ponta Grossa
(PR): Atena Editora, 2019.

Formato: PDF

Requisitos de sistema: Adobe Acrobat Reader

Modo de acesso: World Wide Web

Inclui bibliografia

ISBN 978-85-7247-199-2

DOI 10.22533/at.ed.992191803

1. Bacteriologia. 2. Fungos patogênicos. 3. Medicina. 4. Patologia.
I. Salgado, Yvanna Carla de Souza.

CDD 616.9

Elaborado por Maurício Amormino Júnior – CRB6/2422

O conteúdo dos artigos e seus dados em sua forma, correção e confiabilidade são de responsabilidade exclusiva dos autores.

2019

Permitido o download da obra e o compartilhamento desde que sejam atribuídos créditos aos autores, mas sem a possibilidade de alterá-la de nenhuma forma ou utilizá-la para fins comerciais.

www.atenaeditora.com.br

APRESENTAÇÃO

No volume III da coleção Patologia intitulado: Doenças Bacterianas e fúngicas, apresentamos em capítulos, diversos artigos de pesquisas realizadas em diferentes regiões. A temática contempla a pesquisa básica que inclui estudos sobre os agentes infecciosos, dados epidemiológicos, diagnósticos e tratamentos, bem como temáticas correlacionadas.

O crescimento destas infecções se caracteriza como um grave problema de saúde pública, em especial pelo aumento da resistência microbiológica aos tratamentos disponíveis. Neste sentido, é extremamente importante que os profissionais que atuam na área da saúde conheçam os agentes infecciosos, suas características, seus agravos, suas incidências regionais e sistemas de prevenção e tratamento.

A multidisciplinaridade dos trabalhos apresentados tem como objetivo explorar a produção de conhecimentos sobre as infecções relevantes no Brasil, tais como a sífilis, a tuberculose, hanseníase, infecções fúngicas, entre outras.

A obra é fruto do esforço e dedicação das pesquisas dos autores e colaboradores de cada capítulo e da Atena Editora em elaborar este projeto de disseminação de conhecimento e da pesquisa brasileira. Espero que este livro possa somar conhecimentos e permitir uma visão crítica e contextualizada; além de inspirar os leitores a contribuírem com pesquisas para a promoção de saúde e bem estar social.

Yvanna Carla de Souza Salgado

SUMÁRIO

CAPÍTULO 1	1
O PRÉ-NATAL COMO FERRAMENTA NA PREVENÇÃO DA SÍFILIS CONGÊNITA: UMA REVISÃO INTEGRATIVA DA LITERATURA	
<i>Lorena Sophia Cadete de Almeida Lemos Vilela</i>	
<i>Gisélia Santos de Souza</i>	
<i>Barbara Melo Vasconcelos</i>	
<i>Carolayne Rodrigues Gama</i>	
<i>Larissa Suzana de Medeiros Silva</i>	
<i>Nathália Lima da Silva</i>	
<i>Raíssa Fernanda Evangelista Pires dos Santos</i>	
<i>Luana Carla Gonçalves Brandão Santos</i>	
<i>Karol Bianca Alves Nunes Ferreira</i>	
<i>Alessandra Nascimento Pontes</i>	
<i>Mariana Gomes de Oliveira</i>	
<i>Tânia Kátia de Araújo Mendes</i>	
<i>Thycia Maria Gama Cerqueira</i>	
<i>Keila Cristina Pereira do Nascimento Oliveira</i>	
<i>Maria Luiza de Azevedo Garcia</i>	
<i>Beatriz Santana de Souza Lima</i>	
<i>Hulda Alves de Araújo Tenório</i>	
<i>Marilúcia Mota de Moraes</i>	
<i>Luciana da Silva Viana</i>	
DOI 10.22533/at.ed.9921918031	
CAPÍTULO 2	8
EVOLUÇÃO DECENAL DE SÍFILIS EM GESTANTES NO ESTADO DA BAHIA, BRASIL	
<i>Nilse Querino</i>	
<i>Lucas Carvalho Meira</i>	
<i>Mariana dos Santos Nascimento</i>	
<i>Emmanuelle Gouveia Oliveira</i>	
<i>Bethânia Rêgo Domingos</i>	
<i>Larissa Silva Martins Brandão</i>	
DOI 10.22533/at.ed.9921918032	
CAPÍTULO 3	12
INCIDÊNCIA DE SÍFILIS EM GESTANTES DO DISTRITO SANITÁRIO V DO RECIFE DURANTE O ANO DE 2017	
<i>Liniker Scolfild Rodrigues da Silva</i>	
<i>Camila Mendes da Silva</i>	
<i>Karla Erika Gouveia Figueiredo</i>	
<i>Cristina Albuquerque Douberin</i>	
<i>Cybelle dos Santos Silva</i>	
<i>Silas Marcelino da Silva</i>	
<i>Jailson de Barros Correia</i>	
DOI 10.22533/at.ed.9921918033	
CAPÍTULO 4	23
ANÁLISE DE CASOS DE SÍFILIS CONGÊNITA EM UM HOSPITAL GERAL DE RECIFE- PE	
<i>Glayce Kelly Santos Silva</i>	
<i>Amanda Katlin Araújo Santos</i>	
<i>Ana Paula dos Santos Silva</i>	
<i>Anderson Alves da Silva Bezerra</i>	

Beatriz Mendes Neta
Camila Ingrid da Silva Lindozo
Ezequiel Moura dos Santos
Fernanda Alves de Macêdo
Gislainy Thais de Lima Lemos
Luan Kelwyny Thaywã Marques da Silva
Lucas Chalegre da Silva
Jabes dos Santos Silva
Juliana Beatriz Silva Pereira
Maria Caroline Machado
Marcielle dos Santos Santana
Mirelly Ferreira Lima
Nayane Nayara do Nascimento Galdino
Ramiro Gedeão de Carvalho
Roana Caroline Bezerra dos Santos
Rosival Paiva de Luna Júnior
Silvia Maria de Luna Alves
Sidiane Barros da Silva
Wellington Francisco Pereira da Silva
Maria da Conceição Cavalcante Lira
Viviane de Araújo Gouveia

DOI 10.22533/at.ed.9921918034

CAPÍTULO 5 31

PADRÃO ESPACIAL DA SÍFILIS CONGÊNITA NO ESTADO DE PERNAMBUCO, 2012 – 2017

Amanda Priscila de Santana Cabral Silva
Eliane Rolim de Holanda
Roberta de Souza Pereira da Silva Ramos
Vânia Pinheiro Ramos

DOI 10.22533/at.ed.9921918035

CAPÍTULO 6 41

PANORAMA DA SÍFILIS CONGÊNITA EM JUAZEIRO DO NORTE DE 2013 A 2017

Evanússia de Lima
David Antônio da Silva Marrom
Cristiana Linhares Ribeiro Alencar
Cicero Alexandre da Silva
Kelvia Guedes Alves Lustosa
Liliana Linhares Ribeiro Brito Coutinho
Francimones Rolim Albuquerque
Maria Nizete Tavares Alves

DOI 10.22533/at.ed.9921918036

CAPÍTULO 7 51

ABORDAGEM DA SÍFILIS CONGÊNITA NO MUNICÍPIO DO PAULISTA: UM RELATO DE EXPERIÊNCIA

Juliane Raquel Miranda de Santana
Isabô Ângelo Beserra
Yasmim Talita de Moraes Ramos
Maria Isabelle Barbosa da Silva Brito
Jéssica Emanuela Mendes Morato
Lays Hevécia Silveira de Farias
Rafaely Marcia Santos da Costa
Angelica Xavier da Silva
Leônia Moreira Trajano
Julianne Damiana da Silva Vicente

Isabela Nájela Nascimento da Silva

Ana Márcia Drechsler Rio

DOI 10.22533/at.ed.9921918037

CAPÍTULO 8 57

DISTRIBUIÇÃO ESPACIAL DOS CASOS NOVOS DE HANSENÍASE EM UM ESTADO HIPERÊNDEMICO DO NORDESTE DO BRASIL

Celivane Cavalcanti Barbosa

Cristine Vieira do Bonfim

Cintia Michele Gondim de Brito

Andrea Torres Ferreira

André Luiz Sá de Oliveira

José Luiz Portugal

Zulma Maria de Medeiros

DOI 10.22533/at.ed.9921918038

CAPÍTULO 9 68

ANÁLISE EPIDEMIOLÓGICA DE PACIENTES COM HANSENÍASE EM ALAGOAS ENTRE OS ANOS DE 2014 A 2016

Aldenyelle Rodrigues de Albuquerque

José Victor de Mendonça Silva

Everly Santos Menezes

Luana Karen Correia dos Santos

Susana Paiva Oliveira

Mikael Adalberto dos Santos

Carolinne de Sales Marques

DOI 10.22533/at.ed.9921918039

CAPÍTULO 10 78

ESTRATÉGIA DE DESENHO CASO-CONTROLE PARA INVESTIGAR ASSOCIAÇÃO GENÉTICA NA HANSENÍASE EM UMA POPULAÇÃO ALAGOANA

Everly Santos Menezes

José Victor de Mendonça Silva

Luana Karen Correia dos Santos

Susana Paiva Oliveira

Aldenyelle Rodrigues de Albuquerque

Mikael Adalberto dos Santos

Walcelia Oliveira dos Santos

Jaqueline Fernandes Lopes

Carolinne de Sales Marques

DOI 10.22533/at.ed.99219180310

CAPÍTULO 11 90

AÇÃO DE BUSCA ATIVA “ DIA DO ESPELHO”: ESTRATÉGIA PARA DETECÇÃO DOS CASOS NOVOS DE HANSENÍASE NA CIDADE DO RECIFE: RELATO DE EXPERIÊNCIA

Morgana Cristina Leôncio de Lima

Sâmmea Grangeiro Batista

Ariane Cristina Bezerra Silva Martins

Randal de Medeiros Garcia

Mecciene Mendes Rodrigues

Ana Sofia Pessoa da Costa Carrarini

Eliane Germano

Jailson de Barros Correia

DOI 10.22533/at.ed.99219180311

CAPÍTULO 12 95

MORHAN PERNAMBUCO: AÇÕES EM PROL DO COMBATE À HANSENÍASE EM RECIFE E REGIÃO METROPOLITANA NOS ANOS DE 2016, 2017 E 2018

Mayara Ferreira Lins dos Santos
Randal de Medeiros Garcia
Raphaella Delmondes do Nascimento
Danielle Christine Moura dos Santos
Dara Stephany Alves Teodório
Emília Cristiane Matias de Albuquerque
Giovana Ferreira Lima
Júlia Rebeka de Lima
Marianna Siqueira Reis e Silva
Nataly Lins Sodré

DOI 10.22533/at.ed.99219180312

CAPÍTULO 13 98

QUIMIOCINAS E CITOCINAS EM SORO DE PACIENTES COM HANSENÍASE ATUAM COMO MARCADORES SOROLÓGICOS NAS REAÇÕES HANSÊNICAS

Jamile Leão Rêgo
Nadja de Lima Santana
Paulo Roberto Lima Machado
Léa Cristina de Carvalho Castellucci

DOI 10.22533/at.ed.99219180313

CAPÍTULO 14 116

FARMACODERMIA GRAVE SECUNDÁRIA À POLIQUIMIOTERAPIA PARA HANSENÍASE: RELATO DE CASO

Gabriela Belmonte Dorilêo
Vanessa Evelyn Nonato de Lima
Ackerman Salvia Fortes
Isabelle Cristyne Flávia Goulart de Pontes
Letícia Rossetto da Silva Cavalcante
Luciana Neder

DOI 10.22533/at.ed.99219180314

CAPÍTULO 15 121

O IMPACTO DA TUBERCULOSE COMO UMA DOENÇA NEGLIGENCIADA NO ESTADO DE PERNAMBUCO

Hérica Tavares Milhomem
Aline Alves da Silva Santos
Débora Kathuly da Silva Oliveira
Déborah Tavares Milhomem
Fernanda Chini Alves
Maria Eduarda dos Santos
Maria Carolina de Albuquerque Wanderley
Roberta Luciana do Nascimento Godone

DOI 10.22533/at.ed.99219180315

CAPÍTULO 16 129

TUBERCULOSE PULMONAR: PERFIL EPIDEMIOLÓGICO DO SERTÃO PERNAMBUCANO, BRASIL

Marília Mille Remígio da Costa
David Henrique Vieira Vilaça
Ana Ividy Andrada Diniz
Cícera Amanda Mota Seabra

Edilberto Costa Souza
Ana Valéria de Souza Tavares
Almi Soares Cavalcante
Talles de Araújo Andrade
Nathália Hevén de Lima Feitosa
Kaio Teixeira de Araujo
Thaise de Abreu Brasileiro Sarmiento
Emanuel Victor Cordeiro da Costa Silva

DOI 10.22533/at.ed.99219180316

CAPÍTULO 17 134

MONITORAMENTO DOS CASOS DE TUBERCULOSE RESISTENTE NO MUNICÍPIO DO RECIFE-PE, 2015-2018

Ariane Cristina Bezerra Silva Martins
Silvana Carvalho Cornélio Lira
Mônica Rita da Silva Simplício
Morgana Cristina Leôncio Lima
Ana Sofia Pessoa da Costa Carrarine
Maria Eduarda Moraes Lins
Amanda Queiroz Teixeira
Thaís Patrícia de Melo Bandeira
Eliane Germano
Jailson de Barros Correia

DOI 10.22533/at.ed.99219180317

CAPÍTULO 18 142

AÇÕES CONTINGENCIAIS PARA ENFRENTAMENTO DA TUBERCULOSE NA POPULAÇÃO PRIVADA DE LIBERDADE. RECIFE/PE

Ariane Cristina Bezerra Silva Martins
Silvana Carvalho Cornélio Lira
Sâmmea Grangeiro Batista
Morgana Cristina Leôncio de Lima
Ana Sofia Pessoa da Costa Carrarine
Jailson de Barros Correia

DOI 10.22533/at.ed.99219180318

CAPÍTULO 19 151

ESTUDO DESCRITIVO DOS CASOS DE TUBERCULOSE NOTIFICADOS DO MUNICÍPIO DO PAULISTA, 2007- 2017

Isabô Ângelo Beserra
Yasmim Talita de Moraes Ramos
Maria Isabelle Barbosa da Silva Brito
Jéssica Emanuela Mendes Morato
Juliane Raquel Miranda de Santana
Lays Hevécia Silveira de Farias
Rafaely Marcia Santos da Costa
Angelica Xavier da Silva
Weinar Maria de Araújo
Dayane da Rocha Pimentel

DOI 10.22533/at.ed.99219180319

CAPÍTULO 20 160

PERCEPÇÃO DE PACIENTES COM TUBERCULOSE SOBRE SUA FORMA MULTIRRESISTENTE:
“A LUZ TÍSICA DO MUNDO”

Juliana de Barros Silva
Kátia Carola Santos Silva
Gilson Nogueira Freitas
Mariana Boullitreau Siqueira Campos Barros
Solange Queiroga Serrano
Magaly Bushatsky

DOI 10.22533/at.ed.99219180320

CAPÍTULO 21 171

PROCESSO DE ENFERMAGEM A PACIENTE ACOMETIDA POR TUBERCULOSE URINARIA

Raquel da Silva Cavalcante
Alessandra Maria Sales Torres
Dayana Cecilia de Brito Marinho
Débora Maria da Silva Xavier
Gilson Nogueira Freitas
Hemelly Raially de Lira Silva
Isabela Lemos da Silva
Larissa Farias Botelho
Leidyenne Soares Gomes
Marcielle dos Santos Santana
Nivea Alane dos Santos Moura
Rayara Medeiros Duarte Luz
Viviane de Araújo Gouveia

DOI 10.22533/at.ed.99219180321

CAPÍTULO 22 178

IMPORTÂNCIA DO DIAGNÓSTICO DIFERENCIAL EM CASOS DE TUBERCULOSE MAMÁRIA

Hérica Tavares Milhomem
Aline Alves da Silva Santos
Débora Kathuly da Silva Oliveira
Déborah Tavares Milhomem
Fernanda Chini Alves
Maria Eduarda dos Santos
Maria Carolina de Albuquerque Wanderley
Roberta Luciana do Nascimento Godone

DOI 10.22533/at.ed.99219180322

CAPÍTULO 23 184

TUBERCULOSE NA PÁLPEBRA: UM RELATO DE CASO

Roseline Carvalho Guimarães
Aline Barbosa Pinheiro Bastos
Francine Ribeiro Alves Leite
Samuel Carvalho Guimarães
Emanoella Pessoa Angelim Guimarães
Carlos André Mont'Alverne Silva
Isabela Ribeiro Alves Leite Dias

DOI 10.22533/at.ed.99219180323

CAPÍTULO 24 194

FREQUÊNCIA DAS MICOBACTÉRIAS NÃO TUBERCULOSAS NO PERÍODO DE 2015 A 2017 NO ESTADO DE SERGIPE

Fabiana Cristina Pereira de Sena Nunes
Karenn Nayane Machado Guimarães
Lívia Maria do Amorim Costa Gaspar
Regivaldo Melo Rocha

DOI 10.22533/at.ed.99219180324

CAPÍTULO 25 198

FATORES QUE PREDISPÕEM A MENINGITE BACTERIANA NO PERÍODO NEONATAL

Maryana de Moraes Frota Alves
Ana Maria Fernandes Menezes
Atília Vanessa Ribeiro da Silva
Joana Magalhães Santos

DOI 10.22533/at.ed.99219180325

CAPÍTULO 26 204

ASPECTOS EPIDEMIOLÓGICOS DA LEPTOSPIROSE EM RONDÔNIA NO PERÍODO DE 2014 A 2017

Lucas Justo Sampaio
Alice Soares de Souza

DOI 10.22533/at.ed.99219180326

CAPÍTULO 27 208

PANCREATITE AGUDA EM PACIENTE COM LEPTOSPIROSE

Mariana Ayres Henrique Bragança
Caroline Nascimento Maia
Walleska Karla de Aguiar e Lemes Faria

DOI 10.22533/at.ed.99219180327

CAPÍTULO 28 213

LEPTOSPIROSE CANINA POSSÍVEL CAUSA DE SÍNDROME DA ANGÚSTIA RESPIRATÓRIA AGUDA EM CUIDADOR DE CÃES

Mariana Ayres Henrique Bragança
Caroline Nascimento Maia
Mariana Pinheiro Alves Vasconcelos
Delma Conceição Pereira das Neves
Gladson Denny Siqueira
Stella Ângela Tarallo Zimmerli

DOI 10.22533/at.ed.99219180328

CAPÍTULO 29 217

ESTRATÉGIA EFICAZ PARA O ENFRENTAMENTO DO TRACOMA NO ESTADO DO CEARÁ

Vivian da Silva Gomes
Wagner Robson Germano Sousa
Maria Olga Alencar

DOI 10.22533/at.ed.99219180329

CAPÍTULO 30 230

MANEJO E ANTIBIOTICOTERAPIA EM PNEUMONIA ADQUIRIDA NA COMUNIDADE: RELATO DE CASO

Bárbara Mayã Austregésilo de Alencar
Marconi Edson Maia Júnior
Tatiana Leal Marques
Kátia Mireille Austregésilo de Andrade Alencar

DOI 10.22533/at.ed.99219180330

CAPÍTULO 31 232

AVALIAÇÃO BACTERIOLÓGICA EM AMOSTRAS DE “AÇAÍ NA TIGELA” COMERCIALIZADAS NO MUNICÍPIO DE CARUARU – PE, BRASIL

Vanessa Maranhão Alves Leal
João Pedro Souza Silva
Andrea Honorio Soares
Eduardo da Silva Galindo
Agenor Tavares Jácome Júnior

DOI 10.22533/at.ed.99219180331

CAPÍTULO 32 240

ACTINOMICOSE CEREBRAL: QUESTIONAMENTOS DIANTE DE UMA EVOLUÇÃO CLÍNICA DE 10 ANOS

Vinícius Fernando Alves Carvalho
Nathalie Serejo Silveira Costa
Nathália Luísa Carlos Ferreira
Iza Maria Fraga Lobo
Angela Maria da Silva

DOI 10.22533/at.ed.99219180332

CAPÍTULO 33 249

DOENÇA DE JORGE LOBO: UMA REVISÃO INTEGRATIVA

Marília Mille Remígio da Costa
David Henrique Vieira Vilaça
Ana Ividy Andrada Diniz
Cícera Amanda Mota Seabra
Edilberto Costa Souza
Ana Valéria de Souza Tavares
Almi Soares Cavalcante
Talles de Araújo Andrade
Emanuel Victor Cordeiro da Costa Silva

DOI 10.22533/at.ed.99219180333

CAPÍTULO 34 253

IN VITRO AND IN SILICO ANALYSIS OF THE MORIN ACTION MECHANISM IN YEAST OF THE *Cryptococcus neoformans* COMPLEX

Vivianny Aparecida Queiroz Freitas
Andressa Santana Santos
Carolina Rodrigues Costa
Hildene Meneses e Silva
Thaís Cristina Silva
Amanda Alves de Melo
Fábio Silvestre Ataídes
Benedito Rodrigues da Silva Neto
Maria do Rosário Rodrigues Silva

CAPÍTULO 35 263

INVESTIGAÇÃO EPIDEMIOLÓGICA INÉDITA DE COCCIDIOIDOMICOSE NO SERTÃO PERNAMBUCANO

Adna Maris de Siqueira Martins
Ana Maria Parente Brito
Flávia Silvestre Outtes Wanderley
Kamila Thaís Marcula Lima
Karla Millene Sousa Lima Cantarelli
Maria José Mourato Cândido Tenório

DOI 10.22533/at.ed.99219180335

CAPÍTULO 36 267

ANÁLISE DA PRODUÇÃO CIENTÍFICA SOBRE *Candida auris*

Davi Porfirio da Silva
Igor Michel Ramos dos Santos
Rossana Teotônio de Farias Moreira

DOI 10.22533/at.ed.99219180336

CAPÍTULO 37 281

ANTIMICROBIAL EFFECT OF *Rosmarinus officinalis* LINN ESSENTIAL OIL ON PATHOGENIC BACTERIA IN VITRO

Evalina Costa de Sousa
Alexandra Barbosa da Silva
Krain Santos de Melo
Iriani Rodrigues Maldonade
Eleuza Rodrigues Machado

DOI 10.22533/at.ed.99219180337

CAPÍTULO 38 296

PROBLEMAS RESPIRATÓRIOS EM AGRICULTORES NA UBS DE NATUBA MUNICÍPIO DE VITÓRIA DE SANTO ANTÃO-PE

Glauce Kelly Santos
Amanda katlin Araújo Santos
Angélica Gabriela Gomes da Silva
Beatriz Mendes Neta
Camila Ingrid da Silva Lindozo
Fernanda Alves de Macêdo
Hérica Lúcia Da Silva
Jordy Alisson Barros dos Santos
Juliana Beatriz Silva Pereira
Luan Kelwyny Thaywã Marques da Silva
Maria Caroline Machado Serafim
Nayane Nayara do Nascimento Gaudino
Ramiro Gedeão de Carvalho
Roana Carolina Bezerra dos Santos
Robson Cruz Ramos da Silva
Rosival Paiva de Luna Júnior
Talita Rafaela da Cunha Nascimento
Vivian Carolyne de Matos Gomes
Sidiane Barros da Silva
Wellington Francisco Pereira da Silva
Maria da Conceição Cavalcanti de Lira

SOBRE A ORGANIZADORA..... 304

IN VITRO AND IN SILICO ANALYSIS OF THE MORIN ACTION MECHANISM IN YEAST OF THE *Cryptococcus neoformans* COMPLEX

Vivianny Aparecida Queiroz Freitas

Universidade Federal de Goiás, Instituto de Patologia Tropical e Saúde Pública, Goiânia, Goiás.

Andressa Santana Santos

Universidade Federal de Goiás, Instituto de Patologia Tropical e Saúde Pública, Goiânia, Goiás.

Carolina Rodrigues Costa

Universidade Federal de Goiás, Instituto de Patologia Tropical e Saúde Pública, Goiânia, Goiás.

Hildene Meneses e Silva

Universidade Federal de Goiás, Instituto de Patologia Tropical e Saúde Pública, Goiânia, Goiás.

Thaís Cristina Silva

Universidade Federal de Goiás, Instituto de Patologia Tropical e Saúde Pública, Goiânia, Goiás.

Amanda Alves de Melo

Universidade Federal de Goiás, Instituto de Ciências Biológicas, Goiânia, Goiás.

Fábio Silvestre Ataídes

Universidade Paulista
Goiânia, Goiás.

Benedito Rodrigues da Silva Neto

Universidade Federal de Goiás, Instituto de Patologia Tropical e Saúde Pública, Goiânia, Goiás.

Maria do Rosário Rodrigues Silva

Universidade Federal de Goiás, Instituto de Patologia Tropical e Saúde Pública, Goiânia, Goiás.

Orionalda de Fátima Lisboa Fernandes

Universidade Federal de Goiás, Instituto de Patologia Tropical e Saúde Pública, Goiânia, Goiás.

ABSTRACT: Cryptococcosis is an important opportunistic fungal disease that has as the etiological agent, yeasts belonging to the complex *Cryptococcus neoformans*. In recent years, the resistance of these yeasts to antifungals has increased, causing the need to seek for different therapies for the infection. The molecular docking simulation assists on the search for these new therapies by using a three-dimensional structure of a computationally simulated protein-ligand complex. This work aimed to evaluate the mechanism of action of the morin flavonoid on yeasts of the *C. neoformans* complex, as well as to elucidate potential inhibitors of important enzymes on the fungal cell membrane. First, the action of the compound on ergosterol was evaluated and the action of the morin on the cytoplasmic membrane of *C. gattii* ATCC 24065 was verified using flow cytometry. Afterwards, we applied the Guided Differential Evolution (DGE) method incorporated the Mocker Virtual Docker program

in order to obtain the crystallographic position of the binder for the prediction of protein-binder interaction. The results showed that the morin was able to reduce ergosterol and cause damage on the fungal cell membrane in MIC of 32 $\mu\text{g} / \text{mL}$. Re-docking results for the combination of four search algorithms, four scoring functions and the presence of water molecules tested with the structure of *C. neoformans* Trehalose-6-phosphate phosphatase, generated a RMSD of less than 2 Å. These results showed that the compound has action on the cell membrane of this fungus and trehalose 6-phosphate phosphatase becomes a potential target for elucidation of the mechanism of action involving the cell membrane.

KEYWORDS: *Cryptococcus neoformans*, flavonoid, cell membrane, molecular docking.

RESUMO: A criptococose é uma importante doença fúngica oportunística que tem como agente etiológico, leveduras pertencentes ao complexo *Cryptococcus neoformans*. A resistência dessas leveduras aos antifúngicos tem aumentado nos últimos anos, fazendo com que se busque diferentes terapias para a infecção. A simulação de docking molecular auxilia na busca destas novas terapias, onde utiliza-se uma estrutura tridimensional de um complexo proteína-ligante simulada computacionalmente. Este trabalho objetivou-se em avaliar o mecanismo de ação do flavonoide morina sobre leveduras do complexo *C. neoformans* bem como elucidar potenciais inibidores de enzimas importantes na membrana celular fúngica. Primeiramente foi avaliada ação do composto sobre o ergosterol, e verificada a ação da morina sobre a membrana citoplasmática de *C. gattii* ATCC 24065 usando citometria de fluxo. Em seguida aplicamos o método de evolução diferencial guiada (GDE) implementado no programa Molegro Virtual Docker para obter a posição cristalográfica do ligante para a previsão da interação proteína-ligante. Os resultados mostraram que a morina foi capaz de reduzir o ergosterol e causar lesão de membrana nas células fúngicas na CIM de 32 $\mu\text{g}/\text{mL}$. Análise dos resultados de re-docking para a combinação de quatro algoritmos de busca, quatro funções scores e a presença de moléculas de água realizadas com a estrutura da Trealose-6-fosfato fosfatase de *C. neoformans*, geraram um RMSD menor que 2 Å. Estes resultados mostraram que o composto tem ação sobre a membrana celular deste fungo, e a trealose 6-fosfato fosfatase torna-se um alvo em potencial para elucidação do mecanismo de ação que envolve a membrana celular.

PALAVRAS-CHAVE: *Cryptococcus neoformans*, flavonoide, membrana celular, docking molecular.

1 | INTRODUCTION

During the last century, cryptococcosis has evolved into a major invasive fungal disease and its epidemiology has been substantiated on the main focus of the disease which is a reflex of both the environmental change in exposure to the fungus and of the increase of host risk factors such as the increase of the infection by the Acquired Immunodeficiency Virus (HIV)(HARRIS et al., 2013; PERFECT; BICANIC, 2014). Its etiological agent is yeast species belonging to the complex *Cryptococcus neoformans*,

Cryptococcus neoformans and *Cryptococcus gattii* which are subdivided into different serotypes and genotypes (KWON-CHUNG; VARMA, 2006; LIN; HEITMAN, 2006). The infection is acquired after the inhalation of infective propagules, basidiospores or dehydrated yeasts present in the environment. Upon reaching the pulmonary alveoli, primary infection begins in the lungs and through hematogenous dissemination it can cause from cutaneous lesions to systemic infections (Kwon-Chung et al. 2014). Cryptococcal meningitis is the most frequent clinical form of the disease reported among patients with human immunodeficiency virus, affecting approximately 80% of these patients (HUNG et al., 2007; JARVIS et al., 2014).

The antifungal treatment for cryptococcosis varies according to the extent of the disease, the severity, as well as the immunological state of the host (PERFECT et al., 2010). Although there are some clinical differences between cryptococcosis caused by *C. neoformans* from that caused by *C. gattii*, the recommended treatment for both species are currently identical. The antifungals amphotericin B and fluconazole are the drugs of choice for the treatment of cryptococcal meningitis with the first one being used for induction, while the second is used for consolidation, maintenance and prophylaxis (CHEN et al., 2013; CHEN; MEYER; SORRELL, 2014; GROSSMAN; CASADEVALL, 2016). Resistance to antifungals was previously rare. However, recent reports have described the increase in the minimal inhibitory concentration (MIC) of *C. neoformans* isolates for fluconazole and, to a lesser extent, for amphotericin B in the last decade (CHEN; MEYER; SORRELL, 2014; SMITH et al., 2015). Despite the scarcity of new classes of antifungal drugs that have hit the market in recent years, innovative approaches to drug discovery have driven research into alternative therapeutic strategies (KHAN et al., 2006; LOMBARDI et al., 2015). On this context, plants and their bioactive compounds have been very promising as candidates for the development of new drugs.

Molecular Docking, a computer simulation methodology that can predict the conformation of a protein-drug complex with relatively high accuracy when compared with experimental structures was previously analyzed. Analyses of the interactions between a protein target and a drug can be simulated by these evolutionary algorithms (HEBERLÉ; DE AZEVEDO, 2011).

Morin (3,5,7,2',4'-pentahydroxyflavone) is a yellow polyphenol pigment originally isolated from members of the Moraceae family. Present in many plants, fruits and wine, it has several biological and biochemical effects, such as anti-inflammatory, antioxidant, antidiabetic, antitumor antihypertensive, antibacterial, hypouryemic and neuroprotective actions. (AL-NUMAIR et al., 2014; CASELLI et al., 2016; HUSSAIN et al., 2014; LIN et al., 2013; SELEEM; PARDI; MURATA, 2016; TIAN, 2006; XIE et al., 2006; ZHANG et al., 2010) We evaluated the action of this compound against yeasts of the *C. neoformans* complex, in order to elucidate their possible mechanisms of action.

2 | MATERIALS AND METHODS

2.1 Compound

Morin was purchased from Sigma-Aldrich Company. Solvent for the compound test: dimethylsulfoxide (DMSO).

2.2 Evaluation of the mechanism of action

2.2.1 Ergosterol dosing

The methodology used for extracting ergosterol from yeasts of *C. neoformans* was performed according to the technique developed by ARTHINGTON-SKAGGS et al., (1999). The presence of ergosterol and the late sterol intermediate 24 (28) DHE (Dehydroergosterol) in the extracted sample resulted in a characteristic curve of four peaks. The ergosterol content was calculated as a percentage of the wet weight of the cell by the following equations: % ergosterol + % 24(28)DHE = $[(A_{281} \cdot 5 / 290) \times F] / \text{pellet weight}$, % 24(28)DHE = $[(A_{230} / 518) \times F] / \text{pellet weight}$, and %ergosterol = [% ergosterol+ %24(28)DHE] - %24(28)DHE. F is the dilution factor in ethanol and 290 and 518 are the values of E (in percentages per centimeter) determined for crystalline ergosterol and 24 (28) DHE, respectively.

2.2.2 Effect of morin on the cell membrane of yeasts of *Cryptococcus neoformans*

The evaluation of Morin's mechanism of action was carried out according to Ahmad et al. (2011), with modifications. Cells of *C. gattii* ATCC 24065 were cultured in ASD for 72 hours, inoculated in 10 ml of culture medium RPMI and incubated overnight at 35 ° C in Shaker at 200 rpm. The inoculum was adjusted in a spectrophotometer at a length of 530nm and 85% transmittance, obtaining a concentration of approximately $1-5 \times 10^6$ CFU / ml. The inoculum was added to 5 ml of RPMI broth plus the compound in 4x MIC concentration, 2x MIC, MIC and ½ MIC and incubated at 35°C for 2 hours. Afterwards, the cells were centrifuged for 5 minutes at 5000 rpm, the pellet was resuspended in 5 ml of phosphate buffer (PBS: 8.77 g NaCl, 1.02 g Na₂ HPO₄, 0.34 g NaH₂ PO₄ / L, PH 7.2), centrifuged again for 5 minutes at 5000 rpm and the content after vortexed were transferred to eppendorfs. Cells were centrifuged again for 10 minutes at 5000 rpm, the supernatant discarded and the pellet resuspended in 200 ul PBS.

For cell labeling, 5 µg/mL propidium iodide (PI-Sigma), a membrane integrity marker, was added in all treated cells and on the negative controls. The obtained marker suspension was maintained at 35 ° C for 30 minutes in the absence of light and subsequently submitted to analysis by the Accuri C6 (Becton Dickinson Biosciences) cytometer, with 10,000 events being acquired in a given population (gate), and fluorescence red light used on detector FL2 for PI. (PI) is a marker of membrane integrity with the ability to cross damaged cell membrane, therefore, inside the cell it binds to nucleic acids, emitting red fluorescence, however, when associated with the

intact cell membrane this marker does not emit fluorescence (PINA-VAZ et al., 2001; VALE-SILVA et al., 2006).

2.2.3 Analysis in silico

In the pre-docking analysis we used the enzyme trehalose-6-phosphate phosphatase of *C. neoformans*, PDB access code: 5DX9, resolution 2.5 Å (MIAO et al., 2016) Tps1, and trehalose-6-phosphate phosphatase, Tps2. Here, we report the structures of the N-terminal domain of Tps2 (Tps2NTD). We performed the docking simulation against the active site of 5DX9 and compared the docked poses with the crystallographic structure. In docking simulations, it is expected that the best results generate RMSD values less than 2.0 Å when compared with crystallographic structures

The Guided Differential Evolution (GDE) method was implemented in the Molegro Virtual Docker program to obtain the crystallographic position of the binder in order to predict the protein-binder interaction.

In the present work, all simulations were performed in a MacBook Air (Intel Processor Core i5 Duo, 1.4 GHz, 4 GB SDRAM DDR3 1600 MHz).

3 | RESULTS

Inhibition of ergosterol biosynthesis was evaluated through cellular ergosterol quantification which demonstrated that in 32 µg / mL (MIC), morin reduced fungal cell ergosterol by 59.65%, a higher value when compared to fluconazole MIC. Table 1 shows the results obtained in the test. Fluconazole, used as a positive control showed a reduction of ergosterol in MIC (2 µg / mL) of 53.08%.

Compound / antifungal	MIC	½ MIC
Morin	59,65%	59,43%
Fluconazole	53,08%	40,14%

Table 1. Reduction of ergosterol biosynthesis by the morin compound and antifungal fluconazole in *C. gattii* ATCC 24065




Figure 1. Spectrophotometric profile of *C. gattii* ATCC 24065 sterols, untreated in (a) and after

treatment with the morin compound at concentrations ($\mu\text{g/mL}$) 16 (b) and 32 (c).




Figure 2. Spectrophotometric profile of *C. gattii* ATCC 24065 sterols, untreated in (a), treated with morin at 32 $\mu\text{g/mL}$ (b), and treated with fluconazole at 2 $\mu\text{g/mL}$ (c).

The effect of morin on the fungal plasma membrane was assessed by flow cytometry through the analysis of the cells labeled with the PI marker. As a positive control, 70% ethyl alcohol and 2 $\mu\text{g/mL}$ amphotericin B were used on the cells of *C. gattii* ATCC 24065. Ethyl alcohol 70% caused membrane damage in 99.8% of the analyzed cells as shown in Figure 3 on histogram B and amphotericin presented 26.8% of fungal death as shown in Figure 3 on histogram C. The negative control was performed with untreated *C. gattii* labeled with PI, showing 0.0% of cells with membrane damage (Figure 3, histogram A). After morin incubation period of 2h at 37 ° C, it was observed that the compound promoted lesions in an average of 45.5% of the cells tested.




Figure 3. Histograms showing cells of *C. gattii* ATCC 24065. (A) Autofluorescence control, (B) Control with 70% alcohol, (C) Amphotericin B at concentration of 2 $\mu\text{g/mL}$. The X-axis shows, on a logarithmic scale, the fluorescence intensity of the PI-labeled cells.




Figure 4. Histograms of *C. gattii* ATCC 24065 treated with different concentrations of Morin. The X-axis shows, on a logarithmic scale, the fluorescence intensity of the PI-labeled cells. Gate M1 shows the percentage of cells not non-viable labeled with PI.

Re-docking simulations were performed with the structure of *C. neoformans* Trehalose-6-phosphate phosphatase. Re-docking results for the combination of four search algorithms, four scoring functions and the presence of water molecules (a total of 32 different docking protocols) generated an RMSD of less than 2 Å. The following parameters and their combinations were varied: radius of the docking sphere, number of series, maximum number of interactions and maximum population size demonstrating interactions of hydrogen bonds and van der Waals with residues.




Figure 5. The crystalline structure of the enzyme trehalose-6-phosphate phosphatase of *C. neoformans* (X-ray diffraction (2.5 Å)). A) In red are represented the α -helices and in blue the β -bands. The cavities with potential bonding capacity used in re-docking are in yellow. B) Overlap of the best docking structure generated in the MVD with the ligand Trehalose-6-phosphate (T6P). C) Doping sphere (green) used in molecular docking simulations. Parameters used: radius of the docking sphere (15 Å), number of series (20), maximum population size (50), atomic coordinates ($X = 0.48$, $Y = 22.13$, $Z = 21.00$).

4 | DISCUSSION

In docking simulations, it is expected that the best results generate RMSD values less than 2.0 Å when compared with crystallographic structures. The procedure of

obtaining the crystallographic position of the ligand is often called “re-docking” which is fundamentally a validation method that determines whether the molecular docking algorithm is able to recover the crystallographic position using computer simulation.

The ergosterol is the predominant sterol in the cytoplasmic membrane, as well as the main component of the fungi membrane. It is involved in several biological functions and it is the main target of the antifungals used to treat systemic fungal infections (AHMAD ET AL. 2011, ALCAZAR-FUOLI & MELLADO 2013). Therefore, in our studies we aimed to quantify this sterol in the presence of morin. We obtained promising results when using the morin, such as a reduction of 59.65% of the ergosterol from the standard strain of *C. gattii* ATCC 24065. Other flavonoids showed this same potential, as in the study carried out by Reis et al., (2016) which quantified the ergosterol of *C. neoformans* in the presence of fisetin, and observed a reduction of 25.4% in the concentration of 128 µg/mL. These results suggest that ergosterol is a possible target for flavonoids.

The flow cytometric analysis with PI marker used to evaluate the capacity of the compound in the plasma membrane of the cells, showed that the morin acted on 38.7% of the cells of species *C. neoformans* complex, causing lesion in its membrane. Similar results were found for other flavonoids related to morin, like in the study carried out by DA SILVA et al., (2014) vegetables, grains, flowers, tea, and wine. They differ in their chemical structures and characteristics. Such compounds show various biological functions and have antioxidant, antimicrobial, anti-inflammatory, and antiapoptotic properties. The aim of this study was to evaluate the in vitro interactions of flavonoids with fluconazole against *Candida tropicalis* strains resistant to fluconazole, investigating the mechanism of synergism. Three combinations formed by the flavonoids (+ which reported that the association of flavonoids such as Catechin and Quercetin altered the cell membrane structure of *Candida tropicalis* yeasts resistant to fluconazole, resulting in loss of plasma membrane integrity, causing higher permeability.

5 | CONCLUSION

Natural products offer many biological activities and have a great impact on the discovery of new drugs. The results obtained in our study showed the existence of antifungal activity by the Morin compound against yeasts of the *C. neoformans* complex, in addition to guiding to the possible places of action of this polyphenol.

REFERENCES

AHMAD, A. et al. Fungicidal activity of thymol and carvacrol by disrupting ergosterol biosynthesis and membrane integrity against *Candida*. **European Journal of Clinical Microbiology and Infectious Diseases**, v. 30, n. 1, p. 41–50, 2011.

AL-NUMAIR, K. S. et al. Morin, a flavonoid, on lipid peroxidation and antioxidant status in experimental myocardial ischemic rats. **Tradity Complement Altern Med**, v. 11, n. 3, p. 14–20, 2014.

ALCAZAR-FUOLI, L.; MELLADO, E. Ergosterol biosynthesis in *Aspergillus fumigatus*: Its relevance as an antifungal target and role in antifungal drug resistance. **Frontiers in Microbiology**, v. 3, n. JAN, p. 1–6, 2013.

ARTHINGTON-SKAGGS, B. A et al. Quantitation of Ergosterol Content : Novel Method for Determination of Fluconazole Susceptibility of *Candida albicans*. **Journal of clinical microbiology**, v. 37, n. 10, p. 3332–3337, 1999.

CASELLI, A. et al. Morin: A Promising Natural Drug. **Current medicinal chemistry**, v. 23, n. 8, p. 774–791, 2016.

CHEN, S. C. et al. Antifungal therapy and management of complications of cryptococcosis due to *Cryptococcus gattii*. **Clinical infectious diseases : an official publication of the Infectious Diseases Society of America**, v. 57, n. 4, p. 543–51, 2013.

CHEN, S. C. A.; MEYER, W.; SORRELL, T. C. *Cryptococcus gattii* infections. **Clinical Microbiology Reviews**, v. 27, n. 4, p. 980–1024, 2014.

DA SILVA, C. R. et al. Synergistic effect of the flavonoid catechin, quercetin, or epigallocatechin gallate with fluconazole induces apoptosis in *Candida tropicalis* resistant to fluconazole. **Antimicrobial Agents and Chemotherapy**, v. 58, n. 3, p. 1468–1478, 2014.

GROSSMAN, N. T.; CASADEVALL, A. Physiological Differences in *C. neoformans* *in vitro* versus *in vivo* and Their Effects on Antifungal Susceptibility. **Antimicrobial Agents and Chemotherapy**, n. December, p. AAC.02108-16, 2016.

HARRIS, J. R. et al. *Cryptococcus gattii* infections in multiple states outside the US Pacific Northwest. **Emerging infectious diseases**, v. 19, n. 10, p. 1620–6, 2013.

HEBERLÉ, G.; DE AZEVEDO, W. F. Bio-inspired algorithms applied to molecular docking simulations. **Current medicinal chemistry**, v. 18, n. 9, p. 1339–1352, 2011.

HUSSAIN, J. et al. Isolation and bioactivities of the flavonoids morin and Morin-3-O--D-glucopyranoside from *Acridocarpus orientalis* - A wild arabian medicinal plant. **Molecules**, v. 19, n. 11, p. 17763–17772, 2014.

JARVIS, J. N. et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis: Implications for improving outcomes. **Clinical Infectious Diseases**, v. 58, p. 736–745, 2014.

KHAN, S. et al. Antifungal Susceptibility Testing Method for Resource Constrained Laboratories. **Indian Journal of Medical Microbiology**, v. 24, n. 3, p. 171–176, 2006.

KWON-CHUNG, K. J.; VARMA, A. Do major species concepts support one, two or more species within *Cryptococcus neoformans* ? **FEMS Yeast Research**, v. 6, n. 4, p. 574–587, 2006.

LIN, K.-H. et al. Antioxidant activity of herbaceous plant extracts protect against hydrogen peroxide-induced DNA damage in human lymphocytes. **BMC research notes**, v. 6, p. 490, 2013.

LIN, X.; HEITMAN, J. The biology of the *Cryptococcus neoformans* species complex. **Annu.Rev. Microbiol.**, v. 60, n. 0066–4227 (Print), p. 69–105, 2006.

LOMBARDI, L. et al. Insights into the antimicrobial properties of hepcidins: Advantages and drawbacks as potential therapeutic agents. **Molecules**, v. 20, n. 4, p. 6319–6341, 2015.

MIAO, Y. et al. Structures of trehalose-6-phosphate phosphatase from pathogenic fungi reveal the

mechanisms of substrate recognition and catalysis. **Proceedings of the National Academy of Sciences**, v. 113, n. 26, p. 7148–7153, 2016.

PERFECT, J. R. et al. Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America. **Clinical Infectious Diseases**, v. 50, n. 3, p. 291–322, 2010.

PERFECT, J. R.; BICANIC, T. Cryptococcosis diagnosis and treatment: What do we know now. **Fungal Genetics and Biology**, v. 78, p. 49–54, 13 out. 2014.

PINA-VAZ, C. et al. Cytometric approach for a rapid evaluation of susceptibility of Candida strains to antifungals. **Clinical Microbiology and Infection**, v. 7, n. 11, p. 609–618, 2001.

REIS, M. P. C. et al. Fisetin as a promising antifungal agent against Cryptococcus neoformans species complex. **Journal of Applied Microbiology**, v. 121, n. 2, p. 373–379, 2016.

SELEEM, D.; PARADI, V.; MURATA, R. M. Review of flavonoids: A diverse group of natural compounds with anti-Candida albicans activity in vitro. **Archives of Oral Biology**, v. 76, 2016.

SMITH, K. D. et al. Increased Antifungal Drug Resistance in Ugandan Clinical Isolates of Cryptococcus neoformans. **Antimicrobial Agents and Chemotherapy**, v. 59, n. August, p. AAC.01299-15, 2015.

TIAN, W.-X. Inhibition of fatty acid synthase by polyphenols. **Current Medicinal Chemistry**, v. 13, n. 8, p. 967–977, 2006.

VALE-SILVA, L. A et al. Investigation of the mechanism of action of 3-(4-bromophenyl)-5-acyloxymethyl-2,5-dihydrofuran-2-one against Candida albicans by flow cytometry. **Bioorganic & medicinal chemistry letters**, v. 16, n. 9, p. 2492–5, 2006.

XIE, M.-X. et al. Characterization of the interaction between human serum albumin and morin. **Biochimica et biophysica acta**, v. 1760, n. 8, p. 1184–91, 2006.

ZHANG, Z. et al. Morin exerts neuroprotective actions in Parkinson disease models in vitro and in vivo. **Acta pharmacologica Sinica**, v. 31, n. 8, p. 900–906, 2010.

SOBRE A ORGANIZADORA

Yvanna Carla de Souza Salgado: Possui graduação em Farmácia pela Universidade Estadual de Ponta Grossa (2004), Habilitação em Análises Clínicas (2005), Especialização em Farmacologia (UNOPAR/IBRAS - 2011), Mestrado em Ciências Farmacêuticas pela Universidade Estadual de Ponta Grossa (2013) e Doutorado em Biologia Celular e Molecular pela Universidade Federal do Paraná (2017). Possui experiência técnica como farmacêutica e bioquímica e atualmente trabalha com os temas: farmacologia, biologia celular e molecular e toxicologia.

Agência Brasileira do ISBN
ISBN 978-85-7247-199-2

